Study · Randomized controlled trial · n = 101 · 2024

15 results

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J and 14 more

Show all authors

Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W

Diabetes care1 Jan 2024Cited by 64 (Europe PMC)

PMID37943529PMCIDPMC10733643DOI10.2337/dc23-1287PepBankPUB-37943529

Source link PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with T2D, dulaglutide reduced HbA1c more than placebo at week 20.
In plain wordsIn Chinese adults with diabetes, dulaglutide reduced HbA1c more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 101
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
HbA1c change
−1.35%
dulaglutide
HbA1c change
0.03%
placebo
Source sentences
Summary
Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352914
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide lowered HbA1c from baseline to week 20 more than placebo (changes of -1.41% to -1.67%).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide lowered HbA1c more than placebo after 20 weeks.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change at week 20
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
HbA1c change, smallest
−1.41%
mazdutide
HbA1c change, largest
−1.67%
mazdutide
HbA1c change
0.03%
placebo
Source sentences
Summary
Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was change in HbA1c from baseline to week 20.
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352901
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mean HbA1c changes from baseline to week 20 were -1.41% to -1.67% with mazdutide and -1.35% with dulaglutide.
In plain wordsIn Chinese adults with type 2 diabetes, HbA1c fell by 1.41% to 1.67% with mazdutide and by 1.35% with dulaglutide after 20 weeks.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change at week 20
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg (open label)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
HbA1c change
−1.35%
dulaglutide
Source sentences
Summary
Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was change in HbA1c from baseline to week 20.
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352902
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide reduced body weight dose-dependently, by up to 7.1%, compared with 1.4% with placebo.
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide lowered body weight more than placebo, with larger doses giving larger loss.
Peptide
Mazdutide
Outcome
DecreaseBody weight change at week 20
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Body weight change, largest
−7.1%
mazdutide
Body weight change
−1.4%
placebo
Source sentences
Summary
Mean percent changes in body weight from baseline to week 20 were dose dependent and up to -7.1% with mazdutide (-2.7% with dulaglutide and -1.4% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352903
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, body weight fell by up to 7.1% with mazdutide and by 2.7% with dulaglutide.
In plain wordsIn Chinese adults with type 2 diabetes, body weight fell by up to 7.1% with mazdutide and by 2.7% with dulaglutide after 20 weeks.
Peptide
Mazdutide
Outcome
DecreaseBody weight change at week 20
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg (open label)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Body weight change
−2.7%
dulaglutide
Source sentences
Summary
Mean percent changes in body weight from baseline to week 20 were dose dependent and up to -7.1% with mazdutide (-2.7% with dulaglutide and -1.4% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352904
06HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo reached an HbA1c below 7.0% at week 20.
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo reached an HbA1c below 7.0%.
Peptide
Mazdutide
Outcome
IncreaseShare reaching HbA1c below 7.0%
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352905
07HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo reached an HbA1c of 6.5% or less at week 20.
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo reached an HbA1c of 6.5% or less.
Peptide
Mazdutide
Outcome
IncreaseShare reaching HbA1c of 6.5% or less
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352906
08HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo lost 5% or more of body weight at week 20.
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo lost at least 5% of body weight.
Peptide
Mazdutide
Outcome
IncreaseShare with body weight loss of 5% or more
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352907
09HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo lost 10% or more of body weight at week 20.
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo lost at least 10% of body weight.
Peptide
Mazdutide
Outcome
IncreaseShare with body weight loss of 10% or more
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352908
10HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, diarrhea was a common adverse event with mazdutide (36%).
In plain wordsIn Chinese adults with type 2 diabetes, diarrhea was a common side effect of mazdutide.
Peptide
Mazdutide
Outcome
Not applicableDiarrhea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Incidence
36%
mazdutide
Source sentences
Summary
The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352909
11HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, decreased appetite was a common adverse event with mazdutide (29%).
In plain wordsIn Chinese adults with type 2 diabetes, decreased appetite was a common side effect of mazdutide.
Peptide
Mazdutide
Outcome
Not applicableDecreased appetite
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Incidence
29%
mazdutide
Source sentences
Summary
The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352910
12HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, nausea was a common adverse event with mazdutide (23%).
In plain wordsIn Chinese adults with type 2 diabetes, nausea was a common side effect of mazdutide.
Peptide
Mazdutide
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Incidence
23%
mazdutide
Source sentences
Summary
The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352911
13HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, vomiting was a common adverse event with mazdutide (14%).
In plain wordsIn Chinese adults with type 2 diabetes, vomiting was a common side effect of mazdutide.
Peptide
Mazdutide
Outcome
Not applicableVomiting
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Incidence
14%
mazdutide
Source sentences
Summary
The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352912
14HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, hypoglycemia occurred in 10% of participants on mazdutide and 8% on placebo.
In plain wordsIn Chinese adults with type 2 diabetes, low blood sugar occurred in 10% on mazdutide and 8% on placebo.
Peptide
Mazdutide
Outcome
Not applicableHypoglycemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
3 mg, 4.5 mg or 6 mg · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Incidence
10%
mazdutide
Incidence
8%
placebo
Source sentences
Summary
The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
Report a problemFND-3794352913

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

15HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In Chinese adults with T2D, mean body weight fell in all groups at week 20, by 2.7% with dulaglutide and by 1.4% with placebo.
In plain wordsIn Chinese adults with diabetes, weight fell in every group by week 20, including the placebo group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 101
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−2.7%
dulaglutide
Body weight change
−1.4%
placebo
Source sentences
Summary
Mean percent changes in body weight from baseline to week 20 were dose dependent and up to -7.1% with mazdutide (-2.7% with dulaglutide and -1.4% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dula…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3794352915

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07654062

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Shandong Provincial Hospitaln = 150est. Jul 2026 to est. Jul 2029

Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)

Trial page ClinicalTrials.govUpdated 17 Jun 2026

CompletedPhase 2NCT04965506

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Innovent Biologics (Suzhou) Co. Ltd.n = 2526 Sept 2021 to 11 Jun 2022

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 27 Dec 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC